Evidence map›Paper›PMID 41809030›Full record

ArticleiScience2026

SFMBT2 hypermethylation promotes colorectal cancer progression and is a potential noninvasive biomarker for advanced CRC.

Wei Wang, Ling Yu, Wenyuan He, Jingyi Wu, Yuansen Li, Wenzhi Cui, Danli Ye, Juan Zhou, Ming Xie, Xuwen Lai and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wei WangDepartment of Pathology, General Hospital of Southern Theater Command, People's Liberation Army of China, Guangzhou 510010, China.
Ling YuDepartment of Pathology, General Hospital of Southern Theater Command, People's Liberation Army of China, Guangzhou 510010, China.
Wenyuan HeDepartment of Pathology, General Hospital of Southern Theater Command, People's Liberation Army of China, Guangzhou 510010, China.
Jingyi WuGuangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Yuansen LiDepartment of Pathology, General Hospital of Southern Theater Command, People's Liberation Army of China, Guangzhou 510010, China.
Wenzhi CuiDepartment of Pathology, General Hospital of Southern Theater Command, People's Liberation Army of China, Guangzhou 510010, China.
Danli YeDepartment of Pathology, General Hospital of Southern Theater Command, People's Liberation Army of China, Guangzhou 510010, China.
Juan ZhouDepartment of Oncology, General Hospital of Southern Theater Command, People's Liberation Army of China, Guangzhou 510010, China.
Ming XieDepartment of Pathology, The First Naval Hospital of Southern Theater Command, People's Liberation Army of China, Zhanjiang 510010, China.
Xuwen LaiDepartment of Pathology, General Hospital of Southern Theater Command, People's Liberation Army of China, Guangzhou 510010, China.
Chengyong LeiDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SFMBT2 protein is a Polycomb group protein implicated in transcriptional regulation and cancer biology. Here, we investigated the role of

Indexed as

CancerDiagnostics

Identifiers

PMID41809030
PMCPMC12969127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.